KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Pfizer's Cash & Equivalents rose 2298.53% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 2298.53%. This contributed to the annual value of $1.0 billion for FY2024, which is 6344.2% down from last year.
  • As of Q3 2025, Pfizer's Cash & Equivalents stood at $1.3 billion, which was up 2298.53% from $1.6 billion recorded in Q2 2025.
  • Pfizer's Cash & Equivalents' 5-year high stood at $3.1 billion during Q4 2023, with a 5-year trough of $416.0 million in Q4 2022.
  • Over the past 5 years, Pfizer's median Cash & Equivalents value was $1.8 billion (recorded in 2021), while the average stood at $1.7 billion.
  • Per our database at Business Quant, Pfizer's Cash & Equivalents plummeted by 7860.08% in 2022 and then soared by 58581.73% in 2023.
  • Quarter analysis of 5 years shows Pfizer's Cash & Equivalents stood at $1.9 billion in 2021, then plummeted by 78.6% to $416.0 million in 2022, then surged by 585.82% to $2.9 billion in 2023, then crashed by 63.44% to $1.0 billion in 2024, then rose by 28.76% to $1.3 billion in 2025.
  • Its Cash & Equivalents was $1.3 billion in Q3 2025, compared to $1.6 billion in Q2 2025 and $1.4 billion in Q1 2025.